跳转至内容
Merck
CN

S2190000

舒必利

European Pharmacopoeia (EP) Reference Standard

别名:

(±)-止呕灵, (±)-5-氨基磺酰基-N-[(1-乙基-2-吡咯烷基)甲基]-2-甲氧基苯甲酰胺, (±)-N-1-(乙基-2-吡咯基甲基)-2-甲氧基-5-氨磺酰苯甲酰胺

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C15H23N3O4S
CAS号:
分子量:
341.43
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

sulpiride

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

包装形式

neat

储存温度

2-8°C

SMILES字符串

CCN1CCCC1CNC(=O)c2cc(ccc2OC)S(N)(=O)=O

InChI

1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)

InChI key

BGRJTUBHPOOWDU-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Sulpiride EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Health hazard

警示用语:

Warning

危险声明

预防措施声明

危险分类

Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 2

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Jijun Wang et al.
The Cochrane database of systematic reviews, (1)(1), CD008125-CD008125 (2010-01-22)
Sulpiride may be used in combination with other antipsychotic drugs in the hope of augmenting effectiveness - especially for those whose schizophrenia has proved resistant to treatment. To evaluate the effects of sulpiride augmentation versus monotherapy for people with schizophrenia.
Ichiro M Omori et al.
The Cochrane database of systematic reviews, (2)(2), CD007811-CD007811 (2009-04-17)
Sulpiride is a relatively old antipsychotic drug reputed to have low incidence of adverse effects and an effect on the negative symptoms of schizophrenia. This relatively inexpensive antipsychotic drug has a similar neuropharmacological profile to several novel atypical drugs. To
Sulpiride augmentation for schizophrenia.
Jijun Wang et al.
Schizophrenia bulletin, 36(2), 229-230 (2010-01-12)
P Jenner et al.
Advances in biochemical psychopharmacology, 32, 85-103 (1982-01-01)
It can be said that sulpiride exerts a disinhibitory effect in both depression and schizophrenia but this is not associated with mechanisms through which typical antidepressant or anxiolytic agents act. Sulpiride acts selectively as a dopamine receptor antagonist in the
J H Stubbs et al.
Acta psychiatrica Scandinavica, 102(5), 390-393 (2000-12-01)
Schizophrenic patients who are only partially responsive to clozapine pose a therapeutic challenge. In these circumstances some clinicians would consider adding in a second antipsychotic. We present a case report and review evidence for the efficacy of such augmentation strategies.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门